Abstract
INTRODUCTION: Lung hyperinflation is related to exertional dyspnoea, exercise intolerance and reduced physical activity in COPD patients.
AIMS: To investigate the effects of aclidinium on dynamic hyperinflation, exercise endurance time, physical activity and dyspnoea in COPD patients.
METHODS: This double-blind, randomized, crossover study compared aclidinium bromide 400 µg BID (metered dose; equivalent to aclidinium 322 µg delivered dose) with placebo, each for 3 weeks, in 112 patients with moderate to severe stable COPD (FEV1 1.50 L, 56.7% pred). Patients performed constant load exercise at 75% of peak incremental exercise work rate. The primary endpoint was change from baseline in endurance time at Week 3. Other assessments were dyspnoea (Borg scale), dynamic inspiratory capacity (dIC) and parameters of physical activity (SenseWear® accelerometer).
RESULTS: see table
Change from baseline
CONCLUSIONS: Aclidinium significantly improved dynamic hyperinflation, exercise tolerance, physical activity and dyspnoea compared with placebo in COPD patients.
- © 2013 ERS